SCHEMBL6981146

SCHEMBL6981146

CCCC(CC(=O)N1CCN(c2ccc(F)cc2)CC1)NC(=O)[C@H]1O[C@@H]1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
FOLH1 Q04609 1/20 0.43
POLB P06746 2/20 0.43
GFER P55789 1/20 0.42
CAPN1 P07384 1/20 0.42
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
HBB P68871 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.41
ME2 P23368 1/20 0.40
ME1 P48163 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985573 0.91 CASP1 (0.46) ALDH1A1CAPN1HPGDLMNASMN1; SMN2
SCHEMBL6981304 0.90 CNR1 (0.44) CNR1GFERSMN1; SMN2KMT2AMEN1
SCHEMBL6984525 0.89 GFER (0.46) ALDH1A1GFERHSD17B10L3MBTL1LMNA
SCHEMBL6985160 0.84 MEN1 (0.48) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6981707 0.82 SMN1; SMN2 (0.43) ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A
SCHEMBL6983402 0.77 NPC1 (0.54) ALDH1A1POLBKMT2AMEN1GAA
SCHEMBL6981138 0.77 CAPN1 (0.57) ALDH1A1POLBCAPN1HSD17B10LMNA
SCHEMBL6979227 0.75 GAA (0.39) ALDH1A1POLBCAPN1L3MBTL1SMN1; SMN2
SCHEMBL6982668 0.74 POLB (0.60) ALDH1A1POLBGFERHSD17B10LMNA
SCHEMBL6978571 0.74 KMT2A (0.44) ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed